ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 간질환 치료제 시장 규모는 2024년에 200억 2,075만 달러로, 2032년까지 301억 1,363만 달러에 달할 것으로 예측되며, 2025-2032년의 예측 기간에 CAGR로 5.32%의 성장이 전망됩니다. 세계 간질환 치료제 수요는 주로 간 관련 질환의 유병률 증가에 의해 촉진되고 있습니다. 주요 요인으로는 알코올 소비 증가, 건강에 해로운 식습관, 간 질환과 그 관리에 대한 인식 증가 등이 있습니다. 조기 진단, 의료 접근성 향상, 간 질환 예방을 위한 공중 보건 노력 증가는 시장 확대를 더욱 촉진하고 있습니다. 또한 치료 옵션의 발전과 연구개발에 대한 투자 증가는 2025-2032년의 예측 기간 중 간질환 치료제 시장의 성장을 가속할 것으로 예상됩니다.
간질환 치료제 시장 역학
세계보건기구(WHO)의 2024년 발표에 따르면 2022년 약 2억 5,400만 명이 만성 B형 간염에 감염되어 매년 약 120만 명이 새로 감염되고 있습니다. 또한 최근 PubMed Central에 발표된 '세계 비알코올성 지방간 질환의 유병률과 유병률'이라는 제목의 연구에 따르면 세계 비알코올성 지방간 질환(NAFLD)의 유병률은 인구 1,000명당 47명으로 추정됩니다. B형 간염, C형 간염, 지방간 질환, 간경변증 등 많은 간질환은 장기적인 관리가 필요하므로 간질환 환자 증가는 치료 수요 증가와 직결됩니다.
간질환 치료제 시장의 성장에 기여하는 또 다른 요인은 알코올 소비와 부적절한 식습관 증가로, WHO의 2024년 자료에 따르면 전 세계 15세 이상 인구의 7%인 약 4억 명이 알코올 사용 장애를 앓고 있으며, 이 중 성인 인구의 3.7%인 2억 9천만 명이 알코올 중독을 앓고 있다고 합니다. 알코올 중독을 앓고 있습니다. 과도한 알코올 섭취는 간세포에 지방을 축적시켜 알코올 관련 간 질환의 초기 단계인 지방간 질환을 유발할 수 있습니다. 따라서 알코올 섭취 증가와 식생활의 변화로 인해 간질환 치료제에 대한 수요는 앞으로 더욱 증가할 것으로 예상됩니다.
이러한 성장 촉진요인에도 불구하고 간질환 치료제 시장은 까다로운 규제 당국의 승인 절차, 간질환 치료제 관련 잠재적 부작용 등의 어려움에 직면해 있으며, 이는 시장 확대에 걸림돌이 될 수 있습니다.
북미가 전체 간질환 치료제 시장을 독식할 것으로 예상됩니다.
북미는 2024년 간질환 치료제 시장에서 가장 큰 점유율을 차지합니다. 이는 주로 이 지역의 간질환 유병률 증가, 조기 진단 및 질병 관리에 대한 환자 인식 증가, 강력한 연구개발(R&D) 활동, 높은 알코올 소비율, 고령화 등에 기인한 것으로 분석됩니다.
미국 질병예방통제센터(CDC)의 2023년 자료에 따르면 미국에서는 약 88만 명이 만성 B형 간염을 앓고 있습니다. 간염과 같은 간 질환의 부담 증가는 효과적인 치료 및 관리 솔루션에 대한 수요를 자극하고 시장 성장을 가속하고 있습니다.
또한 National Institute on Alcohol Abuse and Alcoholism(NIAAA)의 2024년 보고서에 따르면 미국의 12세 이상 인구 2억 2,130만 명(이 연령대의 78.5%)이 한 번쯤은 술을 마셔본 경험이 있다고 합니다. 과도한 알코올 섭취는 다양한 간 질환의 주요 위험 요소이며, 간 질환 치료제의 필요성이 증가하고 있습니다.
북미 주요 시장 기업 간의 전략적 제휴는 혁신적인 치료제 개발을 더욱 가속화시키고 있습니다. 예를 들어 길리어드 사이언스(Gilead Sciences, Inc.)는 2024년 2월 CymaBay Therapeutics, Inc.를 주당 32.50달러에 인수하는 최종 계약을 체결하여 길리어드의 간질환 치료제 포트폴리오를 확대했습니다.
간 질환의 높은 유병률, 환자 인식 증가, 알코올 소비 증가, 대규모 R&D 투자, 전략적 산업 제휴 등이 예측 기간 중 북미 간 질환 치료제 시장의 주요 성장 촉진요인으로 작용할 것으로 보입니다.
세계의 간질환 치료제 시장에 대해 조사분석했으며, 시장 규모와 예측, 과거 3년의 제품/기술개발, 시장의 주요 기업, 이용 가능한 기회 등의 정보를 제공하고 있습니다.
목차
제1장 간질환 치료제 시장 보고서 서론
제2장 간질환 치료제 시장 개요
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 간질환 치료제 시장의 주요 요인 분석
간질환 치료제 시장 촉진요인
간질환 치료제 시장 억제요인과 과제
간질환 치료제 시장의 기회
제6장 간질환 치료제 시장의 Porter's Five Forces 분석
제7장 간질환 치료제 시장 평가
제품별
항바이러스제
코르티코스테로이드
면역억제제
화학요법약
면역글로불린
기타 제품
질환별
간염
자가면역질환
암
비알코올성 지방성간질환(NAFLD)
기타
최종사용자별
병원 약국
소매 드러그스토어
지역
북미
유럽
아시아태평양
기타 지역
제8장 간질환 치료제 시장의 기업과 제품 개요
Abbott
Gilead Sciences
GSK plc.
F. Hoffmann-La Roche Ltd.
Astellas Pharma Inc.
Novartis AG
Madrigal Pharmaceuticals
Sanofi
Takeda Pharmaceuticals
Amneal Pharmaceuticals, Inc.
AbbVie Inc.
Alnylam Pharmaceuticals Inc.
Merck & Co., Inc.
Eli Lilly and Company
Exelixis, Inc.
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Bayer AG
Viatris Inc.
Ipsen Pharma
제9장 KOL의 견해
제10장 프로젝트 어프로치
제11장 DelveInsight 소개
제12장 면책사항, 문의
KSA
영문 목차
영문목차
Liver Disease Therapeutics Market by Product (Antiviral Drugs, Corticosteroids, Immunosuppressants, Chemotherapy Drugs, Immunoglobulins, and Others), Disease (Hepatitis, Autoimmune Disorders, Cancer, Non-alcoholic Fatty Liver Disease, and Others), End-Users (Hospital Pharmacy, Retail Drug Stores, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of liver disease and increasing consumption of alcohol and improper diet.
The liver disease therapeutics market was valued at USD 20,020.75 million in 2024, growing at a CAGR of 5.32% during the forecast period from 2025 to 2032 to reach USD 30,113.63 million by 2032. The global demand for liver disease therapeutics is being driven primarily by the rising prevalence of liver-related conditions. Key contributing factors include increasing alcohol consumption, unhealthy dietary habits, and heightened awareness of liver diseases and their management. Growing efforts in early diagnosis, improved access to healthcare, and public health initiatives aimed at liver disease prevention are further supporting market expansion. Additionally, advancements in therapeutic options and increased investments in research and development are expected to propel the growth of the liver disease therapeutics market during the forecast period from 2025 to 2032.
Liver Disease Therapeutics Market Dynamics:
According to the World Health Organization (WHO) 2024, approximately 254 million people were living with chronic hepatitis B infection in 2022, with around 1.2 million new infections each year. Additionally, a recent study published in PubMed Central titled "Global incidence and prevalence of nonalcoholic fatty liver disease" estimated the global incidence of nonalcoholic fatty liver disease (NAFLD) at 47 cases per 1,000 population. The same study stated that the prevalence of NAFLD among adults is 32%, with a higher rate in males (40%) compared to females (26%). The growing number of patients with liver diseases directly translates to a higher demand for treatments, especially since many liver conditions, including hepatitis B and C, fatty liver disease, and cirrhosis, require long-term management.
Another factor contributing to the growth of the liver disease therapeutics market is the increasing consumption of alcohol and improper diet. According to the WHO 2024 data, approximately 400 million people (7% of the global population aged 15 years and older) live with alcohol use disorders, of which 209 million people (3.7% of the adult population) suffer from alcohol dependence. Excessive alcohol intake can lead to fat accumulation in liver cells, a condition known as fatty liver disease, which is the earliest stage of alcohol-related liver disease. Consequently, the rising prevalence of alcohol consumption and poor dietary habits is expected to further boost the demand for liver disease therapeutics in the coming years.
Despite these growth drivers, the liver disease therapeutics market faces challenges such as stringent regulatory approval processes and the potential side effects associated with liver disease therapies, which may hinder market expansion.
Liver Disease Therapeutics Market by Product (Antiviral Drugs, Corticosteroids, Immunosuppressants, Chemotherapy Drugs, Immunoglobulins, and Others), Disease (Hepatitis, Autoimmune Disorders, Cancer, Non-alcoholic Fatty Liver Disease, and Others), End-Users (Hospital Pharmacy, Retail Drug Stores, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the liver disease therapeutics market, the chemotherapy drugs segment is projected to capture a substantial revenue share in 2024. According to Globocan 2022 data, approximately 866,136 individuals were diagnosed with liver cancer globally in 2022. This rising prevalence is a key factor driving the demand for chemotherapy drugs.
Chemotherapy remains a standard treatment option for liver cancer, particularly in advanced stages or when surgery is not feasible. Its effectiveness in shrinking tumors, slowing disease progression, and improving survival rates has made it a preferred therapeutic approach for various liver conditions.
Furthermore, ongoing investments in research and development have led to the introduction of more effective chemotherapy agents. Continuous innovation ensures that chemotherapy remains at the forefront of liver disease treatment. For example, in March 2023, Auransa Inc. partnered with the University of Southern California (USC) to initiate a Phase I clinical trial evaluating AU409, a novel therapy for liver cancers and solid tumors with liver-dominant disease.
Given these factors the increasing incidence of liver cancer, proven therapeutic efficacy, and advancements in drug development the chemotherapy drugs segment is expected to experience significant growth, thereby propelling the overall liver disease therapeutics market during the forecast period.
North America is expected to dominate the overall liver disease therapeutics market:
North America is projected to hold the largest share of the liver disease therapeutics market in 2024. This dominance is primarily driven by the rising prevalence of liver disorders in the region, increasing patient awareness of early diagnosis and disease management, robust research and development (R&D) initiatives, high alcohol consumption rates, and an aging population.
According to the Centers for Disease Control and Prevention (CDC) 2023 data, approximately 880,000 people in the United States live with chronic hepatitis B. The growing burden of liver diseases such as hepatitis is fueling demand for effective treatment and management solutions, thereby driving market growth.
Furthermore, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) 2024 reported that 221.3 million individuals aged 12 and older in the U.S. (78.5% of this age group) have consumed alcohol at some point in their lives. Excessive alcohol consumption is a major risk factor for various liver conditions, increasing the need for liver disease therapeutics.
Strategic collaborations among key market players in North America are further accelerating the development of innovative treatments. For instance, in February 2024, Gilead Sciences, Inc. entered into a definitive agreement to acquire CymaBay Therapeutics, Inc. for USD 32.50 per share in cash, expanding Gilead's portfolio of liver disease therapeutics.
Collectively, the high prevalence of liver diseases, growing patient awareness, increasing alcohol consumption, significant R&D investments, and strategic industry collaborations are key factors propelling the growth of the liver disease therapeutics market in North America during the forecast period.
Liver Disease Therapeutics Market Key Players:
Some of the key market players operating in the liver disease therapeutics market include Abbott, Gilead Sciences, GSK plc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Novartis AG, Madrigal Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, Amneal Pharmaceuticals, Inc., AbbVie Inc., Alnylam Pharmaceuticals Inc., Merck & Co., Inc., Eli Lilly and Company, Exelixis, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Bayer AG, and Viatris Inc.
Recent Developmental Activities in the Liver Disease Therapeutics Market:
In June 2024, Ipsen's Iqirvo(R) received the U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis.
In March 2024, Madrigal Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Key Takeaways From The Liver Disease Therapeutics Market Report Study
Market size analysis for current liver disease therapeutics market size (2024), and market forecast for 8 years (2025 to 2032)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
Key companies dominating the liver disease therapeutics market.
Various opportunities available for the other competitors in the liver disease therapeutics market space.
What are the top-performing segments in 2024? How these segments will perform in 2032?
Which are the top-performing regions and countries in the current liver disease therapeutics market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for liver disease therapeutics market growth in the coming future?
Target Audience Who Can Be Benefited From This Liver Disease Therapeutics Market Report Study
Liver disease therapeutics product providers
Research organizations and consulting companies
Liver disease therapeutics - related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in liver disease therapeutics
Various end-users who want to know more about the liver disease therapeutics market and the latest technological developments in the liver disease therapeutics market.
Frequently Asked Questions For The Liver Disease Therapeutics Market:
1. What is meant by liver disease therapeutics?
Liver disease therapeutics refer to the various treatments and interventions used to manage, treat, and potentially cure diseases and conditions affecting the liver. These therapeutics can include a wide range of approaches depending on the specific liver condition being addressed.
2. What is the market for liver disease therapeutics?
The liver disease therapeutics market was valued at USD 20,020.75 million in 2024, growing at a CAGR of 5.32% during the forecast period from 2025 to 2032 to reach USD 30,113.63 million by 2032.
3. What are the drivers for the global liver disease therapeutics market?
The liver disease therapeutics market is primarily being boosted by the increasing prevalence of liver diseases around the globe. Additionally, increasing consumption of alcohol and improper diet, and growing awareness regarding liver diseases are some of the key factors, which are contributing to the growth of the liver disease therapeutics market during the forecast period from 2025 to 2032.
4. Who are the key players operating in the global liver disease therapeutics market?
Some of the key market players operating in the liver disease therapeutics market include Abbott, Gilead Sciences, GSK plc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Novartis AG, Madrigal Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, Amneal Pharmaceuticals, Inc., AbbVie Inc., Alnylam Pharmaceuticals Inc., Merck & Co., Inc., Eli Lilly and Company, Exelixis, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Bayer AG, and Viatris Inc.
5. Which region has the highest share in the global liver disease therapeutics market?
North America is expected to dominate the overall liver disease therapeutics market during the forecast period, 2025 to 2032. This is due to the growing prevalence of liver disorders in the region. Additionally, growing awareness among patients regarding the importance of early and accurate diagnosis and disease management of liver disorders, the presence of robust research and development initiatives, increasing prevalence of alcohol consumption, and the presence of an aging population are some of the key factors driving the growth of the liver disease therapeutics market in North America.
